Michael Steinberger on how A.I.’s impact on white-collar jobs may transform politics and society.

Agency officials promise fast reviews of new treatments while vowing they will not be a “rubber stamp” for the industry. But patients with rare diseases view recent decisions as signs that the doors are closing on their options.

It has always been expensive, but recently prices have risen faster than inflation.